Avalon GloboCare Corp. reported a significant net loss of $4.48 million for the three months ended March 31, 2026, compared to a net loss of $2.48 million during the same period in 2025, marking an increase of 80.5%. The company's revenue from equity method investments was non-existent in the latest quarter, a decline from $392,677 in the previous year, due to the sale of its 40% stake in Lab Services MSO in February 2025. Total operating expenses rose to $2.72 million, up from $2.18 million, driven primarily by increased advertising and marketing costs, which surged by 194.9% to $209,846.
Avalon’s financial position showed a notable decrease in current liabilities, which fell from $14.15 million at the end of 2025 to $4.44 million by March 31, 2026. This reduction was largely attributed to the sale of its subsidiary, Avalon RT 9, which generated $9 million in proceeds. The company’s total assets decreased from $23.4 million to $16.25 million, primarily due to the reclassification of assets related to discontinued operations. The company’s cash position improved significantly, ending the quarter with $776,000 compared to $109,000 at the end of 2025.
Strategically, Avalon has shifted its focus towards the commercialization of its KetoAir breathalyzer device, which is FDA-approved as a Class I medical device. The company has also expanded its intellectual property portfolio in AI-driven technologies, including automated video production systems. However, it has ceased all laboratory services following the redemption of its investment in Lab Services MSO. The company is also in the process of developing its AI systems through its subsidiary, Avalon Quantum AI.
Looking ahead, Avalon GloboCare faces substantial challenges regarding its liquidity and ability to continue as a going concern. The company reported a working capital deficit of approximately $2.77 million as of March 31, 2026, and has incurred recurring losses, raising doubts about its ability to meet future obligations. Management indicated that the company plans to raise additional capital through equity sales to support its business operations and growth strategies, although there are no assurances that these plans will be successful. The company’s future performance will depend on its ability to generate revenue from its new product lines and secure necessary financing.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. develops and markets precision diagnostic consumer products, primarily the KetoAir breathalyzer, which measures ketosis levels to support diabetic and ketogenic diet management. The company previously offered laboratory testing services but has since exited that segment. It operates mainly in the U.S. market, leveraging FDA-cleared medical device technology combined with AI-driven nutrition software, targeting health-conscious consumers through direct online sales and digital marketing channels.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.